Ipsen Submits Marketing Authorization Applications In The U.S. And Europe For Somatuline® (Lanreotide) In The Treatment Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline® Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

In the European Union, Ipsen has submitted national marketing authorization variations for Somatuline® Autogel® 120mg injection to the drug regulatory authorities in 25 countries.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC